Tenaya Therapeutics (TNYA) Common Equity (2020 - 2026)

Tenaya Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $106.2 million for Q1 2026.

• In Q1 2026, Common Equity fell 11.06% year-over-year to $106.2 million; the TTM figure through Mar 2026 stood at $106.2 million (down 11.06% YoY), while the FY2025 annual figure was $123.3 million, up 32.75% from the prior year.
• Common Equity was $106.2 million for Q1 2026 at Tenaya Therapeutics, down from $123.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $249.1 million in Q1 2022 to a low of $82.9 million in Q3 2025.
• Historically, Common Equity has averaged $156.0 million across 5 years, with a median of $139.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Common Equity jumped 365.16% in 2022, then slumped 42.71% in 2023.
• A 5-year view of Common Equity shows it stood at $243.4 million in 2022, then plunged by 42.71% to $139.4 million in 2023, then plunged by 33.4% to $92.9 million in 2024, then surged by 32.75% to $123.3 million in 2025, then dropped by 13.85% to $106.2 million in 2026.
• The last three Common Equity figures came in at $106.2 million (Q1 2026), $123.3 million (Q4 2025), and $82.9 million (Q3 2025), per Business Quant data.